TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Stereotactic Body Radiotherapy (SBRT) Versus Sublobar Resection for High-Risk Patients Non-Small Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria~* Patients must have a suspicious lung nodule for clinical stage I NSCLC.~* Pathologic confirmation at the time of surgery is acceptable. Patients randomized to SBRT require core biopsy for diagnosis prior to treatment.~* Patient must have a mass ≤ 5 cm maximum diameter by CT size estimate that is clinical stage I (T1N0, T2N0)~* Patient must have a CT scan of the chest and upper abdomen and PET-scan within 60 days prior to date of registration.~* Patient must have an Eastern Cooperative Oncology Group (ECOG) or Zubrod performance status 0, 1, or 2.~* Patient must meet at least one major criteria or meet a minimum of two minor criteria as described below:~Major Criteria:~* Forced expiratory volume in one second (FEV1) ≤ 50% predicted~* Carbon monoxide diffusing capacity (DLCO) ≤ 50% predicted~Minor Criteria:~* Age ≥75~* FEV1 51-60% predicted~* DLCO 51-60% predicted~* Pulmonary hypertension (defined as a pulmonary artery systolic pressure greater than 40 mmHg) as estimated by echocardiography or right heart catheterization~* Poor left ventricular function (defined as an ejection fraction of 40% or less)~* Resting or Exercise Arterial oxygen partial pressure (pO2) ≤ 55 mm Hg or blood oxygen saturation (SpO2) ≤ 88%~* pCO2 \> 45 mm Hg~* Modified Medical Research Council (MMRC) Dyspnea Scale ≥ 3.~Exclusion Criteria~* Patient must not have had previous intra-thoracic radiation therapy.~* No prior malignancy except adequately treated non-melanoma skin cancer, in situ cervical cancer, localized prostate cancer, stage 0 Chronic lymphocytic leukemia (CLL), or other cancer disease-free \> 3 yrs.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Randomized Sublobar Resection (Type: ACTIVE_COMPARATOR): Randomized by computer to receive a sublobar resection.
- Randomized SBRT (Type: ACTIVE_COMPARATOR): Randomized by computer to receive Stereotactic Body Radiotherapy (SBRT).
- Observation Sublobar Resection (Type: ACTIVE_COMPARATOR): Patient decides with doctor to undergo a sublobar resection.
- Observation SBRT (Type: ACTIVE_COMPARATOR): Patient decides with doctor to undergo SBRT.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Strain and Blood Inflammatory Markers as Prognostic Tools for ARDS AMIS (ARDS - Markers of Inflammation - Strain)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Moderate to severe ARDS (Berlin Definition)~* Acute beginning \<1 week~* PaO2/FiO2 ratio ≤ 200 after 24h mechanical ventilation with PEEP≥5cmH2O~* Bilateral opacities on chest X-ray~* Respiratory failure not fully explain by cardiac failure or fluid overload~* Informed consent signed by the next of kin and secondarily by the patient when awake~* Patient with social insurance~No Inclusion criteria~* Age \< 18~* Pregnancy a pregnancy test will be done to women of childbearing age~* Chronic obstructive pulmonary disease~* Severe hypoxemia PaO2/FiO2 \<50% with high PEEP~* Immunosuppressive treatment~* Immunodeficiency onco-hematology, HIV

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Inflammatory markers (Type: OTHER): All patients with inclusion criteria (ARDS moderate and severe: Berlin definition) and absence of non inclusion criteria will have a broncho alveolar wash at day 0 and blood sample every three day to measure inflammatory markers. All patients will receive protective ventilation with low tidal volume and pressures limited (Pplat \<30cmH2O). End-Expiratory Lung Volume and strain will be measured every 6 hours from the inclusion to the extubation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of POMELLA™ Extract to Treat Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men 18 years or older (19 years in BC) with a histologic diagnosis of clinically localized prostate cancer prior to radical prostatectomy as defined by:~  1. Clinical state T1-T2~ 2. PSA \<20~ 3. Gleason score ≤ 7~* ECOG performance status of 0-1.~* Life expectancy greater than 10 years.~* Able to understand and give informed consent.~* Laboratory values must be as follows:~  1. White blood cell count: ≥ 3,000/mm\^3~ 2. Absolute granulocyte count: ≥ 1,500/mm\^3~ 3. Platelets: ≥ 100,000/mm\^3~ 4. Hemoglobin: ≥ 12g/dL~ 5. Serum creatinine: ≤ 1.5 x ULN~ 6. AST: ≤ 2 x ULN~ 7. ALT: ≤ 2 x ULN~ 8. Serum calcium: ≤ ULN~ 9. Total bilirubin: ≤ 1.5 x ULN~Exclusion Criteria:~* Patients who are receiving any other investigational therapy.~* Patients who have received or are receiving any other treatment for their prostate cancer.~* Patients with an active serious infection or other serious underlying medical condition that would otherwise impair their ability to receive protocol treatment.~* Dementia or significantly altered mental status that would prohibit the understanding and/or giving of informed consent.~* Histologic evidence of small cell carcinoma of the prostate.~* Patients who are currently receiving active therapy for other neoplastic disorders will not be eligible for study.~* Patients who are receiving any androgens, estrogens or progestational agents.~* Patients with a known hypersensitivity to pomegranates or composites of the capsules/placebo: hydroxypropyl methylcellulose, silicon dioxide or aerosol.~* Patients who are taking any drugs or natural health products which might impact biochemical tests (some examples include: spironolactone, aprepitant, bexarotene, clarithromycin, itraconazole, ketoconazole, St. John's wort). A washout period of 30 days prior to commencing the study would be necessary for these compounds if required.~* Patients who have chronic active hepatitis.~* Medical conditions, which, in the opinion of the investigators would jeopardize either the patient or the integrity of the data obtained.

- Gender: MALE
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: ACTIVE_COMPARATOR): POMELLA™ 2 x 500mg capsule once daily
- Group 2 (Type: PLACEBO_COMPARATOR): POMELLA™ placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Failed Endometrial Ablation Treatment With Implantable Progesterone (FEAT) Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Previous endometrial ablation~* Pelvic pain and/or vaginal bleeding seeking treatment~Exclusion Criteria:~* Previous or current VTE~* Liver tumour, benign or malignant, or active liver disease~* Undiagnosed abnormal genital bleeding~* Known or suspected breast cancer~* Uncontrolled hypertension~* Allergy to component of etonogestrel implant~* Lack of patient consent

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Etonogestrel implant (Type: EXPERIMENTAL): The participants will receive an etonogestrel 68mg implant

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Epidural Levobupivacaine-sufentanil Versus Epidural Levobupivacaine and Intravenous Ketamine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age between 18 and 75 yrs~* class ASA I, II or III~* lung surgery~Exclusion Criteria:~* Contra-indication to the achievement of epidural analgesia~* Preoperative chronic pain,~* Contra-indication to ketamine~* Hypersensitivity to ketamine or any excipients~* Uncontrolled hypertension,~* Stroke~* Heart failure~* Hepatic porphyria~* Contra-indication to sufentanil~* Hypersensitivity to sufentanil, opioids or any excipients~* Treatment with an opioid agonist-antagonist,~* Contra-indication to levobupivacaine~* Hypersensitivity to levobupivacaine, local anesthetics of the amide or any excipients~* Hypotension, shock

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- iv Ketamine (Type: EXPERIMENTAL): Epidural infusion of levobupivacaine and saline (placebo for sufentanil)and iv infusion of ketamine Up to the third postoperative day (6 PM)
- Sufentanil (Type: ACTIVE_COMPARATOR): Epidural infusion of levobupivacaine (1,25 mg/ml) and sufentanil(1 ml = 50 µg diluted in the 200 ml bag of levobupivacaine) IV infusion of saline (placebo for ketamine)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Second-line Therapy of Unresectable Cholangiocarcinoma by RADIOEMBOLIZATION

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Unresectable intra-hepatic CCK histologically proven~* Tumor progression documented on imaging evaluation ( CT or MRI) according to RECIST criteria version 1.1 after first-line therapy~* Performance status \< 2 ; 4) Bilirubin \< 36 micromol/l~* age \> 18 years~Exclusion Criteria:~* Extra-hepatic metastases~* Uncontrolled biliary obstruction~* Contra-indications to RE.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Yttrium microsphere injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Oral Versus Intravenous Acetaminophen for Postoperative Pain Control

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Provision of signed and dated informed consent form~2. Stated willingness to comply with all study procedures and availability for the duration of the study~3. Female, aged 18-45~4. Ability to take oral medication and be willing to adhere to the study intervention regimen~Exclusion Criteria:~1. Known clinically significant liver disfunction~2. Known allergic reactions to components of acetaminophen such as angioedema, anaphylaxis or other~3. Known current substance use disorder~4. Chronic pain syndrome~5. Weight less than 50 kg

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Oral acetaminophen group (Type: ACTIVE_COMPARATOR): the subjects in this group will receive 1000 mg oral acetaminophen 30-45min prior to oocyte retrieval
- IV acetaminophen group (Type: ACTIVE_COMPARATOR): the subjects in this group will receive 1000 mg IV acetaminophen formulation intraoperatively

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Schizophrenic Patients Taking Part in Integrated Care Program

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Outpatients suffering from schizophrenia, schizoaffective disorder, schizophreni-form disorder, delusional disorder or psychotic disorder not otherwise specified~* Age 18 - 65 years~* Current stable treatment with Seroquel according to SmPC since at least 2 months~* Given consent to take part in an integrated care program prior to study startWritten informed consent to take part in this NIS~Exclusion Criteria:~* Presence of any contraindication as described in the SmPC~* Cancellation of participation in the integrated care program

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- All (Type: None): Schizophrenic outpatients who are treated with Seroquel IR and who are additionally intended to start with an integrated care program

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: An Online Intervention to Reduce Self-Harm Among Persons With High Emotion-Related Impulsivity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* at least 13 years of age~* engaged in mental health care~* evidence of either self-harm or suicidal urges or behavior in the past 3 months~* high levels of emotion-related impulsivity.~Exclusion Criteria:~* inability to adequately take part in the online measures due to problems with intellectual function, language, or other conditions,~* psychosis,~* not currently living in California,~* lack of access to a device to privately complete online modules.

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): Participants will be immediately assigned to the intervention.
- Waitlist control (Type: OTHER): Participants will complete measures before and after a waitlist equivalent to the duration of the intervention, to assess whether change is observed with time and repeated assessment. After the waitlist control, participants will be provided the opportunity to take part in the intervention. In this RDICT design, the pre- post- treatment data will be included in analyses.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Safety and Effectiveness of the Akreos MI Five-0 Intraocular Lens.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must have a clinically documented diagnosis of age-related cataract.~* Subjects must have clear intraocular media other than cataract.~* Subjects must be undergoing primary in-the-bag intraocular lens implantation for the correction of aphakia following continuous curvilinear anterior capsulotomy and phacoemulsification cataract extraction.~Exclusion Criteria:~* Subjects with any anterior segment pathology for which extracapsular phacoemulsification cataract surgery would be contraindicated.~* Subjects with diagnosis of degenerative visual disorder.~* Subjects who have any inflammation or edema (swelling) of the cornea.~* Subjects with immunodeficiency disorders.~* Subjects who have had previous intraocular surgery in the study eye.~* Subjects with incomplete/damaged zonule, or with conditions associated with increased risk of zonular rupture.~* Subjects with chronic use of systemic steroids or immunosuppressive medications.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Akreos MI Five-O (Type: EXPERIMENTAL): Accommodating intraocular lens

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women of age 18-65 years (Argentina the minimum age will be 24 years of age)~* Patients randomized in parent study who complete CN162-006 and CN162-007 who consent to enter the rollover study.~* Patient not randomized in parent study that meet inadequate response criteria~Exclusion Criteria:~* Patients who represent a significant risk of committing suicide based on the clinical judgment of the investigator, history or routine psychiatric status exam.~* Patients with a Cardiovascular System Organ Class adverse event(s) occurring in parent study (CN162-006 or CN162-007), that in the investigators judgment is clinically significant and would impact safety of the subject in the current study \[including but not limited to left bundle branch block, or prolonged QT interval corrected (QTc)\].~* In addition, patients should be excluded if they have any laboratory test, vital sign, electrocardiogram (ECG) or clinical findings that in the investigator's judgment is clinically significantly abnormal and could impact the safety of the patient or the interpretation of study assessments in the current study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1: Placebo + BMS-820836 (0.5 mg/day) (Type: EXPERIMENTAL): None
- Arm 2: Placebo + BMS-820836 (1 mg/day) (Type: EXPERIMENTAL): None
- Arm 3: Placebo + BMS-820836 (2 mg/day) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Endoscopic Electrothermic Procedure of the Sacroiliac Joint

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Subject age 18 - 85 years;~* SIJ arthropathy and chronic lower back pain (CLBP);~* Patient to undergo endoscopic electrothermic ablation of spinal levels S1-S3. The L4-L5 and/or L5-S1 facet joint can be included in the ablation per doctor discretion.~* Correct spinal levels (ranging L4-S3) to be treated have been confirmed by 1) diagnostic SIJ injection, followed by 2) diagnostic Medial/Lateral Branch Block at the applicable levels.~* The subject is likely to follow standard of care post-operative follow-up for at least 24 months.~Exclusion Criteria:~Patients receiving additional invasive back surgery after the study treatment.~* Inability to complete follow-up visits or required questionnaires.~* Non-compliant patients~* Difficult or impossible communication with the patient~* Breastfeeding, pregnant or patients who plan a pregnancy while participating in the study~* Systemic neurological disorders with mobility limitations (e.g. advanced Parkinson's disease or multiple sclerosis)~* Patients with incompatibilities or known limitations that make participation impossible~* Patients after stabilization with implants on thoracic or lumbar spine.~* Inability to provide informed consent without a legally authorized representative.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Treatment: Endoscopic ET on SI joint (Type: EXPERIMENTAL): New techniques have been developed and tested to expand the usefulness of minimally invasive spine surgery beyond disk herniation. This includes endoscopic electrothermic ablation which can be used to target SIJ-associated CLBP. A small retrospective study demonstrated significant improvements in Visual Analog Scale and Oswestry Disability Index from pre-operative levels in patients with CLBP associated with the SIJ for up to 21 months following the procedure. However, there has not yet been a prospective study to assess the efficacy of this procedure, and therefore, this is the aim of this study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Trial of Intravenous Vitamin C in Refractory Non-Hodgkin Lymphoma (NHL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age greater than 18 years old~* Aggressive or very aggressive NHL~* Failed one or more therapies~* Patients must not have progressed within 60 days of last therapy~* Not received allogeneic stem cell transplant~* No reasonable standard therapeutic options available~* Glucose 6 phosphate dehydrogenase status normal~* ECOG performance status 0-2~* Normal creatinine and transaminase~* Women of child-bearing potential confirm negative pregnancy test~Exclusion Criteria:~* Significant co-morbid disorders~* Significant psychiatric symptoms~* Smoking~* Excessive alcohol or drug use~* Enrollment in other experimental therapy~* Active infection~* Patients experiencing ongoing response to recent treatments~* Patients who have received chemotherapy within 30 days or biological therapy within 6 weeks

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Intravenous vitamin C

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues